North Immunology

North Immunology is a pre-clinical stage biotechnology company focused on developing bispecific antibodies that target orthogonal inflammatory pathways to treat immune and inflammatory diseases. The company's lead candidate, NOR-101, is a half-life extended bispecific antibody targeting interleukin-13 (IL-13) and interleukin-18 (IL-18) designed to inhibit both type 2 and non-type 2 inflammation driving atopic dermatitis. In September 2026, North Immunology announced a definitive reverse merger agreement with Aethlon Medical to go public, accompanied by a $180 million private placement from leading healthcare investors. The combined company will operate under the North Immunology name and trade on the Nasdaq under the ticker symbol NRTX, with clinical trials for NOR-101 projected to begin in early 2027.